Clinical trials: EGFR Uncommon Mutations
- Condition EGFR Uncommon Mutations
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Mutations in Exons 18 to 21
Pathomolecular Analysis of Rare EGFR Mutations in Advanced NSCLC
While current mutational analyses comprise exons 19 and 21 in which the majority of EGFR-mutations occur, this study aims at investigating the relevance of exon 18 and 20 mutations.
- Trial name
- NCT01215474
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Provitro GmbH